Navigation Links
DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
Date:3/27/2013

Los Angeles, CA (PRWEB) March 27, 2013

The drug safety advocates at DrugRisks.com are announcing updated legal news on the site for patients who have taken the diabetes drug Actos. The first trial began this month for a retired man who alleges he developed bladder cancer after taking the medication.

DrugRisks was created to provide those taking popular prescription drugs like Actos with the latest safety alerts, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

Health experts with the FDA and European Medicines Agency* have warned that use of Actos for extended amounts of time may be linked to an increased risk of bladder cancer. Regulators in France and Germany have also banned its use**.

In the United States, as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals over allegations of bladder cancer***. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

Now, DrugRisks has learned that the first Actos lawsuit trial began this month in California for a retired man who alleges the drug has left him terminally ill from bladder cancer***. At the trial, a former pharmacologist for Takeda testified that the company was more concerned with continued sales of the drug rather than the safety of patients***.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/actos-lawsuit/prweb10573586.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Frozen Food Production in the US Industry Market Research Report from IBISWorld has Been Updated
2. Fitment Guide Update for the 2012 Land Rover Range Rover Evoque, Made by SizeItUp
3. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
4. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
5. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
6. Update: Number of Stryker Rejuvenate Hip Recall Lawsuits Growing in New Jersey Multicounty Litigation, Announces Wright & Schulte LLC
7. Harmonic Software Systems Announces an Updated Version of Their DigitalMeds iPhone App
8. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
9. Updated stereo EEG workflow simplifies planning of epilepsy surgery
10. American Emu Association Updates Quality Regulations in Response to Fraudulent Oils in Market
11. Tylenol Liver Failure Allegation Lawsuits Update: Resource4thePeople Reports Hearing to Consolidate Federal Cases Is Scheduled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... FL (PRWEB) , ... May 06, 2016 , ... ... will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via Discovery ... the vision of becoming a leader in optimized drug discovery through innovative cellular ...
(Date:5/6/2016)... ... , ... Online HR/benefits platforms offer a range of benefits functions to employers ... health plans. “ The Rapid Emergence of Online Benefits Firms: Strategies for Health Plans ... will offer an accurate picture of online benefits today, and the possible risks and ...
(Date:5/6/2016)... ... 06, 2016 , ... Canadian author Mark Black is a speaker, author, and life ... around the world … with the help of his publisher Strategic Book Group and its ... in a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning ... and operated for over 35 years. Maintaining core values of exceptional customer service, quality ... and made them a leading name in San Diego plumbing, and other services including ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of Military ... corporate training, and the National Military Family Association, a nonprofit that works to ... second full-tuition scholarship recipient of 2016. , “Being awarded this scholarship by ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
(Date:5/4/2016)... time for an upgrade. There are many medical recorders on the market but none ... DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller ... innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology: